Curated News
By: NewsRamp Editorial Staff
June 04, 2026
Kairos Pharma Expands Pipeline with CL-741 Acquisition
TLDR
- Kairos Pharma's acquisition of CL-741 could give it an edge in targeting EGFR-mutated lung cancer with a Phase 1-ready asset.
- Kairos Pharma plans to acquire CL-741, a c-MET inhibitor, and advance ENV-105 trials in prostate and lung cancers with $8M funding.
- Kairos Pharma's pipeline aims to overcome drug resistance, potentially improving outcomes for patients with hard-to-treat cancers.
- Kairos Pharma's CL-741, an oral c-MET inhibitor, targets EGFR-mutated lung cancer and is entering Phase 1 trials.
Impact - Why it Matters
This news matters because Kairos Pharma's expansion into c-MET inhibition with CL-741 could provide a new treatment option for patients with EGFR-mutated lung cancer, a disease with high unmet need. The company's focus on overcoming drug resistance, particularly through ENV-105 targeting CD105, has the potential to improve outcomes for prostate and lung cancer patients. With over $8 million in non-dilutive funding, Kairos is well-positioned to advance its pipeline, which may lead to more effective therapies and better survival rates for cancer patients.
Summary
Kairos Pharma (NYSE American: KAPA) has announced a mid-year 2026 update that includes plans to expand its oncology pipeline by acquiring worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor, from Celyn Therapeutics. This candidate is designed to target EGFR-mutated lung cancer and other cancers. The acquisition would complement Kairos Pharma's existing portfolio, which includes ENV-105, KROS-201, KROS-102, and ENV-205. The company expects to initiate a Phase 1 study for CL-741, advance ongoing clinical trials for ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific conferences, and pursue pharmaceutical collaborations. Additionally, Kairos Pharma has secured over $8 million in non-dilutive funding to support its preclinical and clinical programs. Based in Los Angeles, California, Kairos Pharma focuses on overcoming drug resistance and immune suppression in cancer using structural biology. Its lead candidate, ENV-105, targets CD105 to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. ENV-105 is currently in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. Notably, the news was disseminated via the Dynamic Brand Portfolio @ IBN, which includes TinyGems, a specialized communications platform for small-cap and mid-cap companies. TinyGems provides access to a vast network of wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution to millions. This announcement underscores Kairos Pharma's commitment to addressing unmet medical needs in oncology through innovative therapies and strategic partnerships.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma Expands Pipeline with CL-741 Acquisition
